DE69700464T2 - Verfahren zur hemmung der leaderless-proteinausscheidung mittels herzglykosiden, deren aglykone, oder derivate - Google Patents

Verfahren zur hemmung der leaderless-proteinausscheidung mittels herzglykosiden, deren aglykone, oder derivate

Info

Publication number
DE69700464T2
DE69700464T2 DE69700464T DE69700464T DE69700464T2 DE 69700464 T2 DE69700464 T2 DE 69700464T2 DE 69700464 T DE69700464 T DE 69700464T DE 69700464 T DE69700464 T DE 69700464T DE 69700464 T2 DE69700464 T2 DE 69700464T2
Authority
DE
Germany
Prior art keywords
inhibiting
aglycones
derivatives
leaderless protein
leaderless
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69700464T
Other languages
English (en)
Other versions
DE69700464D1 (de
Inventor
Robert Florkiewicz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Application granted granted Critical
Publication of DE69700464D1 publication Critical patent/DE69700464D1/de
Publication of DE69700464T2 publication Critical patent/DE69700464T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69700464T 1996-02-12 1997-02-12 Verfahren zur hemmung der leaderless-proteinausscheidung mittels herzglykosiden, deren aglykone, oder derivate Expired - Fee Related DE69700464T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/599,895 US5891855A (en) 1996-02-12 1996-02-12 Inhibitors of leaderless protein export
PCT/US1997/002237 WO1997028808A1 (en) 1996-02-12 1997-02-12 Methods of inhibiting leaderless protein export using cardiac glycosides or aglycones therefrom and derivatives

Publications (2)

Publication Number Publication Date
DE69700464D1 DE69700464D1 (de) 1999-10-07
DE69700464T2 true DE69700464T2 (de) 2000-04-06

Family

ID=24401543

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69700464T Expired - Fee Related DE69700464T2 (de) 1996-02-12 1997-02-12 Verfahren zur hemmung der leaderless-proteinausscheidung mittels herzglykosiden, deren aglykone, oder derivate

Country Status (9)

Country Link
US (4) US5891855A (de)
EP (2) EP0828497B1 (de)
JP (1) JPH11500454A (de)
AT (1) ATE183922T1 (de)
AU (1) AU706644B2 (de)
CA (1) CA2242245A1 (de)
DE (1) DE69700464T2 (de)
ES (1) ES2140215T3 (de)
WO (1) WO1997028808A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2281925A1 (en) * 1997-02-26 1998-09-03 Ciblex Corporation Inhibitors of leaderless protein export
US6306613B1 (en) 1997-02-26 2001-10-23 Ciblex Corporation Modulators of leaderless protein export and methods for identifying and using the same
US5910484A (en) * 1997-05-30 1999-06-08 The General Hospital Corporation Treatment of ischemic cardiac malfunction
GB9716273D0 (en) 1997-07-31 1997-10-08 Kimberly Clark Ltd Hand cleanser
GB9725480D0 (en) * 1997-12-01 1998-01-28 Univ London Cytokines and their use in the treatment of established chronic infections and cancers
AUPP249298A0 (en) * 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
CZ295108B6 (cs) 1998-03-20 2005-05-18 Benitec Australia Ltd Syntetický gen obsahující dispergovanou nebo cizorodou deoxyribonukleovou molekulu a genový konstrukt obsahující tento syntetický gen
JP2002536415A (ja) * 1999-02-12 2002-10-29 セルパス インコーポレイテッド 抗腫瘍療法
WO2000063364A2 (en) * 1999-04-21 2000-10-26 American Home Products Corporation Methods and compositions for inhibiting the function of polynucleotide sequences
US6423885B1 (en) * 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
IL138529A0 (en) * 2000-09-18 2003-09-17 Yeda Res & Dev High level expression of heterologous proteins
US7112434B2 (en) * 2001-05-02 2006-09-26 University Of South Florida Vector system for selection of genes encoding secreted proteins and membrane-bound proteins
US20040082521A1 (en) * 2002-03-29 2004-04-29 Azaya Therapeutics Inc. Novel formulations of digitalis glycosides for treating cell-proliferative and other diseases
WO2003099011A1 (en) * 2002-05-28 2003-12-04 Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Cardiac glycosides to treat cystic fibrosis and other il-8 dependent disorders
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7560528B2 (en) * 2003-06-20 2009-07-14 Efthimios Ippikoglou Method of producing recombinant DNA molecules
WO2005060951A2 (en) * 2003-12-19 2005-07-07 Bionaut Pharmaceuticals, Inc. Anti-neoplastic agents, combination therapies and related methods
DE102004036047A1 (de) * 2004-07-24 2006-02-23 Bioghurt Biogarde Gmbh & Co. Kg Physiologisch aktive Zusammensetzung
US20080027010A1 (en) * 2004-09-02 2008-01-31 Bionaut Pharmaceuticals, Inc. Treatment of refractory cancers using Na+/K+-ATPase inhibitors
US20060135442A1 (en) * 2004-09-02 2006-06-22 Bionaut Pharmaceuticals, Inc. Pancreatic cancer treatment using Na+/K+ ATPase inhibitors
US20070105790A1 (en) * 2004-09-02 2007-05-10 Bionaut Pharmaceuticals, Inc. Pancreatic cancer treatment using Na+/K+ ATPase inhibitors
US20060135468A1 (en) 2004-09-02 2006-06-22 Bionaut Pharmaceuticals, Inc. Treatment of refractory cancers using NA+/K+ ATPase inhibitors
US20060135441A1 (en) * 2004-09-02 2006-06-22 Bionaut Pharmaceuticals, Inc. Combinatorial chemotherapy treatment using Na+/K+ ATPase inhibitors
EP1812010A2 (de) * 2004-10-18 2007-08-01 BTG International Limited Verwendung von na+/k+ atpase-hemmern und ihren antagonisten
US20060205679A1 (en) * 2004-10-22 2006-09-14 Azaya Therapeutics, Inc. Topical and oral formulations of cardiac glycosides for treating skin diseases
WO2007089688A2 (en) * 2006-01-31 2007-08-09 The University Of Toledo Na/k-atpase ligand
CN109503584A (zh) 2006-05-04 2019-03-22 勃林格殷格翰国际有限公司 多晶型
EP1852108A1 (de) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Zusammensetzungen von DPP-IV-Inhibitoren
PE20080251A1 (es) * 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
CN101541319B (zh) 2006-10-31 2013-09-18 托莱多大学 Src和Src家族激酶的Na+/K+-ATP酶特异性肽抑制剂/激活剂
WO2009064657A1 (en) * 2007-11-13 2009-05-22 Phoenix Biotechnology Inc. Method of determining the probability of a therapeutic response in cancer chemotherapy with cardiac glycoside
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
KR101717301B1 (ko) * 2008-10-14 2017-03-16 네리엄 바이오테크놀로지, 인크. 강심 배당체의 추출방법 및 조성물
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EP2477494B1 (de) 2009-09-16 2015-11-11 The University of Toledo Na/k-atpase-liganden, ouabain-antagonisten, assays damit und verwendungen davon
WO2011088210A1 (en) 2010-01-13 2011-07-21 The University Of Toledo Materials and methods related to sodium/potassium adenosine triphosphatase and src
CN102203112B (zh) 2010-01-15 2014-05-07 苏州润新生物科技有限公司 某些化合物、组合物及方法
US9226960B2 (en) 2010-04-16 2016-01-05 Andrew B. Bush FGF modulation of in vivo antibody production and humoral immunity
US8435525B1 (en) 2010-04-16 2013-05-07 Andrew B. Bush FGF modulation of in vivo antibody production and humoral immunity
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
WO2012103810A1 (en) 2011-02-02 2012-08-09 Suzhou Neupharma Co., Ltd Certain chemical entities, compositions, and methods
CN102219821A (zh) * 2011-05-05 2011-10-19 沈阳药科大学 一类强心苷类化合物及其抗肿瘤用途
EP3453713B1 (de) * 2012-04-29 2021-09-08 Neupharma, Inc. Bufadienolid-verbindungen, die in position 3 durch eine amingruppe substituiert sind, zur verwendung bei der behandlung von krebs
WO2013169793A2 (en) * 2012-05-09 2013-11-14 Ipierian, Inc. Methods and compositions for tdp-43 proteinopathies
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
US9561245B2 (en) * 2012-09-06 2017-02-07 The Board Of Regents Of The University Of Texas System Combination treatments for melanoma
US9572828B2 (en) 2013-07-18 2017-02-21 The Board Of Regents Of The University Of Texas System Treatment for melanoma
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5872103A (en) * 1986-11-26 1999-02-16 Belletti; Dino A. Prevention of mammary tumors by treatment with cardiac glycosides
US5545623A (en) * 1994-06-10 1996-08-13 Akira Matsumori Method of inhibiting secretion of inflammatory cytokines
US5556963A (en) 1994-08-05 1996-09-17 Oklahoma Medical Research Foundation Synthesis of 4-alkoxy-N-acetylneuraminic acid
WO1996004921A1 (en) * 1994-08-13 1996-02-22 Hong Keun Chung TNFα-SECRETION INHIBITOR CONTAINING SYRINGIN OR ITS AGLYCONE
US5627195A (en) * 1995-04-11 1997-05-06 Massachusetts Eye And Ear Infirmary Treatment for ocular inflammation

Also Published As

Publication number Publication date
EP0828497B1 (de) 1999-09-01
AU706644B2 (en) 1999-06-17
EP0941733A2 (de) 1999-09-15
CA2242245A1 (en) 1997-08-14
JPH11500454A (ja) 1999-01-12
DE69700464D1 (de) 1999-10-07
US6281197B1 (en) 2001-08-28
AU2123197A (en) 1997-08-28
EP0941733A3 (de) 1999-12-01
US6107283A (en) 2000-08-22
ES2140215T3 (es) 2000-02-16
ATE183922T1 (de) 1999-09-15
EP0828497A1 (de) 1998-03-18
WO1997028808A1 (en) 1997-08-14
US6071885A (en) 2000-06-06
US5891855A (en) 1999-04-06

Similar Documents

Publication Publication Date Title
DE69700464D1 (de) Verfahren zur hemmung der leaderless-proteinausscheidung mittels herzglykosiden, deren aglykone, oder derivate
NO903059D0 (no) Ligander og reseptorer omfattende nevnte ligander, fremgangsmaate for deres fremstilling og anvendelse.
DE69326937D1 (de) Kombination von Antihormonale und bindende Moleküle zur Krebsbehandlung
DK0991421T3 (da) Påvisning og modulering af IAP'er og NAIP i forbindelse med diagnose og behandling af proliferativ sygdom
WO1998035985B1 (en) Protein markers for lung cancer and use thereof
NO930011D0 (no) Tilfeldig boi-oligomer bibilotek og fremgangsmaate for syntese og anvendelse derav
DE69027168T2 (de) Verfahren zum Vorhersagen der Eigenschaften biologischer Materie, unter Verwendung der Spektrumanalyse im Nah-Infrarot
NO20003818L (no) Fremgangsmåte og innretning for behandling av kroppsvev med elektrisitet eller medikamenter
DE68924114T2 (de) Führungsinstrument zum Durchbohren der Knochenrinde, geeignet zum Auffinden der Löcher von Marknägeln.
NO873753L (no) Periodisk biologisk luftbehandlingsprosess og system for denne.
FI943028A0 (fi) Happoa kestävä FGF-koostumus ja menetelmä ruoansulatuskanavassa esiintyvien, haavaumia aiheuttavien sairauksien hoitamiseksi
DE69735436D1 (de) Methode zum nachweis von zell-apoptose
DK1011723T3 (da) 88KDA tumorgen vækstfaktor og antagonister
DK0584145T3 (da) Fremgangsmåde til in vitro-diagnosticering af kromosomanomalier, der er forbundet med CMT1a-sygdom
IT8645744A0 (it) Sistema di guida per gruppi di ante di porte scorrevoli allineate complanarmente in chiusura, particolarmente per armadi esimili.
DE3766213D1 (de) Glycosidationskatalysator und verfahren zur herstellung von glycosid-derivaten.
Hiroi et al. Involvement of gicerin, a cell adhesion molecule, in development and regeneration of chick sciatic nerve
DE3577865D1 (de) Verfahren zur stabilisierung hydroxylgruppenhaltiger polymere des butadiens oder seiner substituierten derivate.
DE3864381D1 (de) Verfahren und vorrichtung zum kontinuierlichen herstellen gekruemmter prolifstaebe mittels eines zwischenbandes.
ATE323103T1 (de) Proteinmarker für ösophaguskrebs
DE69014569D1 (de) Methode zum Behandeln schlechter Herzfunktion.
ATE407944T1 (de) Mit trp-proteinen verwandtes protein mtr1 und dieses codierende dna-sequenz
DE69521281D1 (de) Verfahren zur Herstellung von menschlichem oder humanem Matrilysin mittels rekombinanter DNA.
SU619185A1 (ru) Способ лечени злокачественных опухолей органов малого таза
DE68911305T2 (de) Das lungenwachstum stimulierende und hemmende faktoren für krebstumorzellen.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee